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ARTICLE
mTORC2-AKT signaling to ATP-citrate lyase drives
brown adipogenesis and de novo lipogenesis
C. Martinez Calejman1, S. Trefely2,3,4, S.W. Entwisle 5,6, A. Luciano1, S.M. Jung1, W. Hsiao1, A. Torres2,3,
C.M. Hung1, H. Li1, N.W. Snyder 4, J. Villén 5,6, K.E. Wellen 2,3 & D.A. Guertin1,7*
mTORC2 phosphorylates AKT in a hydrophobic motif site that is a biomarker of insulin
sensitivity. In brown adipocytes, mTORC2 regulates glucose and lipid metabolism, however
the mechanism has been unclear because downstream AKT signaling appears unaffected by
mTORC2 loss. Here, by applying immunoblotting, targeted phosphoproteomics and meta-
bolite proﬁling, we identify ATP-citrate lyase (ACLY) as a distinctly mTORC2-sensitive AKT
substrate in brown preadipocytes. mTORC2 appears dispensable for most other AKT actions
examined, indicating a previously unappreciated selectivity in mTORC2-AKT signaling. Res-
cue experiments suggest brown preadipocytes require the mTORC2/AKT/ACLY pathway to
induce PPAR-gamma and establish the epigenetic landscape during differentiation. Evidence
in mature brown adipocytes also suggests mTORC2 acts through ACLY to increase carbo-
hydrate response element binding protein (ChREBP) activity, histone acetylation, and gluco-
lipogenic gene expression. Substrate utilization studies additionally implicate mTORC2 in
promoting acetyl-CoA synthesis from acetate through acetyl-CoA synthetase 2 (ACSS2).
These data suggest that a principal mTORC2 action is controlling nuclear-cytoplasmic acetyl-
CoA synthesis.
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A cell’s capacity to sense and respond to nutrients isessential for metabolic homeostasis and losing this ﬂex-ibility is a hallmark of diabetes and cancer. The mam-
malian target of rapamycin (mTOR) kinase is a master regulator
of intracellular metabolism that responds to insulin signaling and
nutrient availability. Its biochemical functions are split between
two complexes called mTOR complex 1 (mTORC1), which
contains the essential subunit Raptor, and mTOR complex 2
(mTORC2), which contains the essential subunits Rictor and
Sin11,2. Amino acids and insulin stimulate mTORC1 to promote
protein, lipid, and nucleic acid synthesis through well-deﬁned
downstream signaling networks. mTORC2 promotes glycolysis
and lipid synthesis; however, its regulation and downstream
mechanisms are less well deﬁned.
The best understood biochemical function of mTORC2 is to
phosphorylate the hydrophobic motif (HM) site in AKT (S473 in
AKT1; S474 in AKT2; S472 in AKT3)3. HM phosphorylation
cooperates with 3-phosphoinositide-dependent kinase 1 (PDK1)-
dependent phosphorylation in the T-loop (T308 in AKT1; T309
in AKT2; T307 in AKT3) to maximally stimulate AKT catalytic
activity4,5. Growth factors facilitate AKT phosphorylation by
stimulating AKT and PDK1 recruitment to the plasma membrane
through pleckstrin homology (PH) domains, which bind phos-
phatidylinositol 3,4,5-triphosphate (PIP3). mTORC2 and PDK1
additionally co-regulate the related AGC family kinases SGK and
PKCα6–9. These substrates lack PH domains, thus their interac-
tion with mTORC2 and PDK1 is likely facilitated by a different
mechanism4. However, the temporal and spatial regulation of
mTORC2 signaling remains poorly understood.
Many models show mTORC2 as an obligatory AKT acti-
vator1,5; however, its exact function in downstream AKT signal-
ing in vivo remains elusive because, in many tissue-speciﬁc
conditional Rictor knockout (KO) models, mTORC2 loss has
seemingly minimal-to-no effect on the phosphorylation of several
AKT substrates2,10. For example, conditionally deleting Rictor in
brown adipose tissue (BAT) (e.g., with ucp1-cre or myf5-cre) or in
white adipose tissue (WAT) (with adiponectin-cre) ablates AKT
HM phosphorylation without obviously impairing AKT activity
toward classic substrates, including PRAS40, TSC2, GSK3β,
AS160, and FoxO110–14. Yet, despite seemingly normal AKT
signaling, Rictor loss profoundly downregulates transcription of
ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), and
fatty acid synthase (FASN), which catalyze de novo lipogenesis
(DNL)11,12. Rictor loss also reduces glucose uptake and inhibits
the expression of ChREBPβ12,13, which is a constitutively active
isoform of the carbohydrate response element binding protein
(ChREBP) transcription factor that stimulates carbohydrate and
lipid metabolic gene expression15. Similarly, inducible deletion of
Rictor in brown preadipocytes has seemingly no effect on
downstream AKT signaling, yet renders these cells incapable of
differentiating in vitro11. Nevertheless, expressing recombinant
AKT1 containing a phospho-mimetic S473 residue in Rictor-
deﬁcient preadipocytes rescues differentiation. The latter obser-
vation suggests that mTORC2 may be more essential for some
AKT actions that are required for brown adipocyte differentiation
and de novo lipogenesis, but dispensable for many others.
ACLY cleaves extra-mitochondrial citrate to generate acetyl-
CoA, which is the precursor for glucose-dependent de novo lipid
and cholesterol biosynthesis. Acetyl-CoA is also used to acetylate
lysine residues on histones and metabolic proteins to regulate
gene expression and enzyme activity, respectively. ACLY serine
455 lies within a basophilic phosphorylation motif (RxxS) that is
similar to the AKT consensus motif (RxRxxS/T). Phosphorylation
of this site stimulates ACLY activity; however, the serine 455
kinase remains controversial as AKT16, PKA17,18, mTOR19, or
the branched chain ketoacid dehydrogenase kinase20 can
reportedly phosphorylate this site. Nevertheless, because ACLY
functions at the interface of glucose-dependent DNL and epige-
netic control of gene expression, it is poised to be a key link
between hormonal signaling and carbohydrate and lipid meta-
bolism in adipocytes.
Here we test the hypothesis that mTORC2 promotes brown
adipocyte differentiation and glucose-driven DNL (gluco-lipo-
genesis) through a distinctly mTORC2-dependent AKT pathway.
To do this, we analyzed mTORC2-regulated AKT phosphosites
and metabolites by mass spectrometry. This led us to identify a
subset of AKT substrates and metabolites that are regulated by
mTORC2, including the enzyme ACLY and its product acetyl-
CoA. We provide evidence that ACLY functions downstream of a
uniquely mTORC2-dependent AKT pathway required for DNL,
differentiation, histone acetylation, and ChREBPβ and gluco-
lipogenic gene expression. Substrate utilization studies suggest an
additional role for mTORC2 in promoting acetyl-CoA synthesis
from acetate through acyl-CoA synthetase short chain family
member 2 (ACSS2). These data uncover a previously unappre-
ciated selectivity in mTORC2-dependent AKT signaling in Ric-
tor-deleted brown adipocytes and reveal mTORC2’s central role
in controlling nuclear–cytoplasmic acetyl-CoA synthesis.
Results
Stratiﬁcation of AKT substrates by mTORC2 sensitivity. To
test the hypothesis that some AKT substrates are more sensitive to
mTORC2 loss than for others and to identify the mechanism by
which mTORC2 drives brown preadipocyte differentiation, we
conducted a targeted phosphoproteomics assay comparing the
insulin response between Rictor-iKO precursor brown adipocytes
(Rictor-iKOPBAs) and isogenic control brown preadipocytes. We
designed the assay to quantify phosphopeptides encompassing
regulatory phosphorylation sites on AKT, previously reported AKT
and SGK substrate sites, and other potential mTORC2 effectors.
Rictor-iKOPBAs maintain growth-factor-stimulated AKTT308 phos-
phorylation, albeit at lower levels, and seemingly normal phos-
phorylation of AKT substrates [Supplementary Fig. 1A], as
previously observed11. Rictor-iKOPBAs and their vehicle-treated
isogenic controls were then serum deprived, or serum deprived and
then stimulated with insulin for 15min. Phosphopeptide-enriched
samples were analyzed with parallel reaction monitoring targeted
mass spectrometry, a highly sensitive quantitative technique. The
assay quantiﬁed 31 known AKT substrates, of which 17 increase
phosphorylation at least 1.5-fold in response to insulin in wild-type
(WT) cells at Benjamini–Hochberg 5% false detection rate (FDR),
indicating that they are likely targets of insulin-stimulated AKT
action. Of the 17 insulin-upregulated phosphopeptides, 9 contain
AKT substrate motifs for which the phosphorylated residue can be
localized with high conﬁdence. The other eight contain phos-
phorylated residues with ambiguous localization within at most
three residues away from the predicted AKT substrate site.
Based on quantitative differences between conditions, we
stratiﬁed phosphopeptides into three classes, all with a 5% FDR
from analysis of variance (ANOVA; see “Methods”): Class I
contains phosphosites that are highly dependent upon mTORC2;
Class II contains phosphosites that are insensitive to mTORC2
loss; and Class III contains phosphosites that are partially
sensitive to mTORC2 loss [Fig. 1a, Supplementary Data 1].
Among the Class I peptides, we identiﬁed the known direct
mTORC2 target sites pAKT1S473, pAKT2S474, and pAKT3S472 as
insulin stimulated and highly sensitive to mTORC2 loss [Fig. 1b,
Supplementary Fig. 2A]. We also identiﬁed a Class I peptide from
NDRG1 with phosphorylation on either S364 or T366 that was
not signiﬁcantly stimulated by insulin but is highly dependent of
mTORC2 [Fig. 1b]. This difference is not explained by changes to
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NDRG1 protein levels as measured by mass spectrometry.
pNDRG1T366 is known to be phosphorylated by SGK, a kinase
from the same family of AKT that requires mTORC2-dependent
HM phosphorylation for its activation6. These ﬁndings conﬁrm
our ability to identify phosphorylation sites that occur with or
without insulin stimulation for which mTORC2 is essential.
Among the Class II substrates, for which mTORC2 is
dispensable, we identiﬁed several AKT target sites, including
pPRAS40T246 and pGSK3βS9 [Fig. 1c, Supplementary Fig. 2B],
validating our previously observed immunoblot analyses using
phospho-speciﬁc antibodies [Supplementary Fig. 1A]11. Also
included in Class II are pTSC2S939 and pTSC2S981, two well-
known AKT phosphorylation events that stimulate the mTORC1
pathway21 [Fig. 1c, Supplementary Fig. 2B]. Consistently,
ribosomal protein S6 peptides containing phosphorylation at
S235 or S236 and at S240 (often used as an mTORC1 activity
reporter) are also Class II substrates [Supplementary Fig. 2B]. We
additionally identiﬁed several predicted AKT substrates that fall
into Class III, showing partial sensitivity to mTORC2 loss
[Fig. 1d, Supplementary Fig. 2C]. One peptide is from a region in
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Fig. 1 Identiﬁcation of mTORC2-sensitive phosphorylation sites, including S455 in ATP citrate lyase (ACLY). a Phosphoproteomics work ﬂow and
analysis in Rictor-iKOPBAs. Colored circles correspond with the type of motifs analyzed (n= 6 per group). b, c Motifs were stratiﬁed by their sensitivity to
mTORC2 loss as being highly sensitive Class I sites (b), insensitive Class II sites (c), or partially sensitive Class III sites (d). e Western blots of protein
lysates from control and Rictor-iKOPBA cells using the indicated total and phospho-speciﬁc antibodies. Cells growing in DMEM were either serum deprived
(−FBS) or serum deprived and then stimulated with fresh serum for 15 min (+FBS) prior to lysis. f Western blots of protein lysates treated as in e with or
without the AKT inhibitor MK2206. g Western blots using lysates from HEK293 cells in which Rictor was deleted by CRISPR/Cas9 genome editing. The
AKT inhibitor MK2206 (10 μM) was administered 1 h prior to lysis in both f and g.
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phosphofructo kinase-2 (PFK2) containing either the annotated
AKT substrate site S486 or the nearby S489, and another is from a
region in ACLY containing the S455 site [Fig. 1d]. We also
identify mTORC2-sensitive sites on BAD (S155) and vimentin
(S39) [Supplementary Fig. 2C]. These data suggest that there is
selective inhibition of AKT signaling pathways following induced
Rictor deletion in brown preadipocytes.
Immunoblotting with commercially available phosphosite-
speciﬁc antibodies independently uncovered serum and insulin-
stimulated pACLYS455 as an AKT substrate showing mTORC2
dependency [Fig. 1e, Supplementary Fig. 1B]. We were unable to
detect pPFK2S486 using a commercially available antibody.
Importantly, pACLYS455 and pPRAS40T246 (an mTORC2-
insensitive AKT substrate in our assays [Fig. 1c, f, Supplementary
Fig. 1B]) are both sensitive to the AKT inhibitor MK2206 [Fig. 1f,
Supplementary Fig. S1B]. This argues against an AKT compen-
satory kinase acting in the absence mTORC2. Serum or insulin-
stimulated pACLYS455, but not pPRAS40T246, is also mTORC2
dependent in HEK293E cells deleted for Rictor using CRISPR/
Cas9, while both sites are sensitive to MK2206 [Fig. 1g,
Supplementary Fig. 1C]. We also expressed recombinant Rictor
in the Rictor-deleted HEK293E cells to conﬁrm that this restores
ACLYS455 phosphorylation [Supplementary Fig. 1D]. Thus
selectivity may be relevant in other Rictor-deleted cell types.
mTORC2 regulates acetyl-CoA availability. The identiﬁcation of
pACLYS455 and pPFK2S486/S489 as mTORC2-sensitive AKT
substrates is interesting because they function at key rate-limiting
regulatory steps in the synthesis of acetyl-CoA from glucose
[Fig. 2a]. ACLY cleaves mitochondria-exported citrate to generate
nuclear–cytoplasmic acetyl-CoA and oxaloacetate. PFK-2 cata-
lyzes the synthesis of fructose-2,6-bisphosphate (F2,6BP) to
allosterically activate PFK-1-mediated synthesis of F1,6BP, which
can also allosterically activate ACLY17. For both enzymes,
phosphorylation at the mTORC2-sensitive site stimulates activ-
ity16,22, suggesting that a key mTORC2 action may be to sti-
mulate acetyl-CoA synthesis.
We also measured the steady-state abundance of 139 additional
metabolites representing intermediary metabolism, 113 of which
were detected in control and Rictor-iKOPBAs [Supplementary
Data 2]. Consistent with an acetyl-CoA synthesis defect,
acetylcarnitine (which derives from acetyl-CoA and carnitine in
a fast and reversible reaction typically in equilibrium with
nuclear–cytoplasmic acetyl-CoA23) decreases by 35.04% in
Rictor-iKOBPAs [Fig. 2b]. Acetylserine and pantothenic acid, both
of which contribute to Coenzyme A synthesis, are also reduced by
23.6% and 12.1%, respectively [Supplementary Data 2]; the latter
possibly resulting from de-repressed pantothenate kinase activ-
ity24. While most glycolytic intermediates are unaffected by Rictor
loss, F1,6BP decreases by 49.1% [Fig. 2c], which could be due to
the mTORC2-sensitive phosphosite in PFK-2 [Fig. 1d]. We also
observe a 42.5% decrease in citrate, the tricarboxylic acid (TCA)
cycle intermediate exported from the mitochondria and used by
ACLY to generate acetyl-CoA [Fig. 2d]. It cannot be determined
from these data as to whether this represents the intra- or extra-
mitochondrial citrate fraction; nevertheless, this could reﬂect a
metabolite-driven negative feedback effect or inherent instability.
The only metabolite that signiﬁcantly increases is the TCA cycle
intermediate malate (by 29.6%) [Fig. 2d], possibly reﬂecting
reduced demand for citrate to be exported. Taken together, these
data support the notion that a principal mTORC2 function in
intermediary metabolism is regulating acetyl-CoA levels.
To directly test whether mTORC2 regulates acetyl-CoA levels,
we used stable isotope dilution liquid chromatography–mass
spectrometry with 13C315N1-labeled acyl-CoA internal standards
to measure total cellular acetyl-CoA levels25,26. This revealed a
43.54% decrease in acetyl-CoA in Rictor-iKOBPAs [Fig. 2e]. We
also measured DNL from glucose via acetyl-CoA intermediates
using a C14-glucose tracer assay. This shows a 48.1% reduction in
lipid synthesis in Rictor-iKOBPAs relative to controls [Fig. 2f].
Quantitative PCR and western blotting indicate that ACLY, ACC,
and FASN mRNA and protein levels are similar in control and
Rictor-iKO precursors [Supplementary Fig. 1E, F], consistent with
decreased lipogenic ﬂux. Thus integrating results from immuno-
blotting, phosphoproteomics, and metabolomics points to ACLY
as a distinctly mTORC2-sensitive AKT substrate.
mTORC2 drives brown adipocyte differentiation through
ACLY. To test whether a defect in ACLY phosphorylation
explains why mTORC2-deﬁcient brown preadipocytes cannot
differentiate, we ﬁrst determined whether ACLY itself is required
for differentiation. To this end, we generated Acly-iKOPBAs and
subjected them to a differentiation assay [Fig. 3a–c]. Indeed, Acly-
iKOPBAs are incapable of differentiating as indicated by their
inability to induce Pparγ2 mRNA or protein [Fig. 3b, Supple-
mentary Fig. 3A] and synthesize lipid droplets [Fig. 3c] in a
differentiation assay. Similar results were obtained with two of the
three independent short hairpin RNAs (shRNAs) designed to
target ACLY [Supplementary Fig. 3B, C]. This conﬁrms that
mTORC2 and ACLY are both necessary for brown adipocyte
differentiation.
To determine whether mTORC2 and ACLY might function in
the same pathway, we asked whether rescuing ACLYS455
phosphorylation in Rictor-iKOPBAs is sufﬁcient to restore their
ability to differentiate. As shown previously11, Rictor-iKOPBAs
cannot induce Pparγ 2 [Fig. 3b] or synthesize lipid droplets
[Fig. 3c] in a differentiation assay. Next, we expressed empty
vector (EV) or recombinant Myc-ACLY-WT, Myc-ACLY-S455A,
or Myc-ACLY-S455D in Rictor-iKOPBAs [Supplementary Fig. 3D]
and differentiated them. Expressing Myc-ACLY-S455D in Rictor-
iKOPBAs restores lipid droplet synthesis (to 108.0% of control)
[Fig. 3d] and the expression of Pparγ2 mRNA (to 74.1% of
control) and protein [Fig. 3e, Supplementary Fig. 3E]. ACLY-
S455D also restores total acetyl-CoA levels in Rictor-iKOPBAs to
higher than control levels (150.2%) [Fig. 3f]. Thus rescuing ACLY
S455 phosphorylation is sufﬁcient to rescue differentiation and
acetyl-CoA synthesis in Rictor-iKOPBAs. In contrast, neither
vector control nor ACLY-S455A restores lipid droplet synthesis,
Pparγ2 expression, or acetyl-CoA levels [Fig. 3d–f]. Interestingly,
overexpressing ACLY-WT slightly rescues lipid droplet synthesis
(to 19.2% of control) [Fig. 3d] and Pparγ2 expression (to 39.0% of
control) [Fig. 3e]. However, ACLY-WT does not increase total
cellular acetyl-CoA levels [Fig. 3f], consistent with S455
phosphorylation being required for maximal ACLY activity.
These data support a model in which ACLY is a critical mTORC2
effector during brown adipogenesis.
ACLY stimulation requires AKT HM phosphorylation. That
pACLYS455 is partially sensitive to mTORC2 loss while direct
mTORC2 sites at pAKT1S473 and pAKT2S474 are highly sensitive
is consistent with mTORC2 indirectly stimulating ACLY. More-
over, expressing recombinant AKT1-S473D in Rictor-iKO brown
preadipocytes mostly rescues their ability to differentiate11. These
data suggest that AKT1 may be the intermediary between
mTORC2 and ACLY during brown adipogenesis, rather than
mTORC2 directly phosphorylating ACLY19. Indeed, recombinant
AKT1-S473D but not AKT1, AKT1-S473A, AKT2, or AKT2-
S474D rescues ACLYS455 phosphorylation [Fig. 4a], consistent
with ACLY being an mTORC2-dependent AKT1 substrate in
brown preadipocytes.
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To further test this hypothesis, we generated Akt1-iKOBPAs and
Akt2-iKOBPAs for comparison in a differentiation assay [Fig. 4b].
Like Rictor-iKOPBAs, only the Akt1-iKOBPAs are incapable of
synthesizing lipid droplets in a differentiation assay [Fig. 4c],
which is in agreement with previous studies11,27. Consistently,
Akt1-iKOBPAs have reduced pACLYS455 phosphorylation [Fig. 4b]
and reduced acetyl-CoA levels (by 41.2%) [Fig. 4d]. Moreover, the
ability of Akt1-iKOBPAs to differentiate is rescued with Myc-
ACLY-S455D (and to a lesser extent with Myc-ACLY-WT)
[Fig. 4e, f]. Notably, Myc-ACLY-S455D does not rescue total
acetyl-CoA levels [Fig. 4g]. This is consistent with total AKT1
deletion having broader effects on glucose-dependent acetyl-CoA
synthesis than losing only HM phosphorylation. Further
consistent with this notion, glucose uptake is reduced by 37.8%
in Akt1-iKOBPAs compared to only a 10.89% in Rictor-iKOPBAs
[Supplementary Fig. 4A]. These data support a model in which
mTORC2-dependent AKT1 HM phosphorylation stimulates
ACLY to promote brown adipocyte differentiation.
If our hypothesis is correct, then we reasoned that brown
preadipocytes lacking only the AKT1 HM phosphorylation site,
in contrast to total Akt1 deletion, should phenocopy Rictor loss
with respect to ACLY phosphorylation and differentiation. To
test this, we generated Akt1-iKOPBAs expressing either EV or
recombinant HA-AKT1-WT, HA-AKT1-S473A, or HA-AKT1-
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Fig. 2 mTORC2 regulates acetyl-CoA levels and glucose-dependent fatty acid synthesis. a Schematic of metabolic pathways and individual metabolites
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synthesized lipids (n= 5 per group). Bar graphs represent mean ± SEM. **p < 0.01 and ***p < 0.001. Statistical signiﬁcance was calculated by using two-
tailed unpaired Student’s t test (b, e, f) or two-way ANOVA with Sidak’s test multiple comparisons (c, d).
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S473D. In the Akt1-iKOPBAs-expressing EV, pACLYS455 and
pPRAS40T246 are both attenuated, while in the HA-AKT1-WT-
and HA-AKT1-S473D-expressing cells, both sites are phosphory-
lated as expected [Fig. 4h]. Importantly, pACLYS455, but not
pPRAS40T246, decreases in the HA-AKT1-S473A-expressing cells
[Fig. 4h]. Moreover, while HA-AKT1-WT- and HA-AKT1-
S473D-expressing cells can differentiate and restore the acetyl-
CoA levels, HA-AKT1-S473A cells are incapable [Fig. 4i, j,
Supplementary Fig. 3F]. We obtained similar results with Akt1,2,3
triple KO precursors [Supplementary Fig. 3G, H]. These data
conﬁrm that mTORC2-dependent AKT1 HM phosphorylation
stimulates ACLY and brown preadipocyte differentiation.
A glucose uptake deﬁciency is not limiting upon mTORC2
loss. Because adipocyte mTORC2 loss impairs glucose uptake
in vivo12–14,28, we had considered the possibility that a glucose
uptake deﬁciency might be preventing Rictor-iKOPBAs from dif-
ferentiating. This seemed unlikely as Rictor-iKOPBAs have a
relatively minor defect in glucose uptake [Supplementary
Fig. 4A], and moreover, intracellular and G6P levels are normal
[Fig. 2c and Supplementary Data 2]. Nevertheless, we tested
whether overexpressing the facilitative glucose transporter Glut1
(the main glucose transporter in preadipocytes) in Rictor-iKOPBAs
can rescue differentiation. Despite Glut1 overexpression more
than doubling glucose uptake into Rictor-iKOPBAs and to levels
equivalent with Glut1-overexpressing control cells, this fails to
rescue differentiation [Supplementary Fig. 4B–D]. Similarly,
overexpressing WT (HK-WT) or hyperactive hexokinase-2 (HK-
T473D), which traps glucose inside the cell by phosphorylating
the glucose 6 carbon and has previously been linked to
mTORC229, also fails to rescue differentiation [Supplementary
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Fig. 3 ACLY is the critical mTORC2 effector during brown adipocyte differentiation. a Western blot showing ablation of ACLY protein and AKT
phosphorylation upon brief 4-OHT treatment of Acly-iKOPBA cells. b, c Acly-iKOPBA and Rictor-iKOPBA cells were differentiated and pparγ2 mRNA expression
(n= 6 per group) (b) and Oil Red O (ORO) staining of lipids (c) were quantiﬁed at day 10 to determine differentiation efﬁciency. Scale bar represents 50
μm. d, e Representative differentiation rescue experiments showing ORO staining (d) and Pparγ2 mRNA expression (n= 6 per group) (e) in Rictor-iKOPBA
cells stably expressing empty (EV), Myc-ACLY-WT, Myc-ACLY-S455A, or Myc-ACLY-455D constructs. Percentage of ORO in d is relative to empty
vector control. Scale bar represents 50 μm. f Direct acetyl-CoA measurements of Rictor-iKOPBA cells (n= 9 per group) stably expressing empty (EV), Myc-
ACLY-WT, Myc-ACLY-S455A, or Myc-ACLY-455D constructs. Bar graphs represent mean ± SEM. ***p < 0.001. a represents ***p < 0.001 vs control (EV),
and b represents ***p < 0.001 vs Rictor-iKOPBA (EV). Statistical signiﬁcance was calculated by using two-way ANOVA with Sidak’s test multiple
comparisons (b, e, f).
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Fig. 4E, F]. Thus neither a glucose uptake nor a trapping defect is
a major limiting factor for the differentiation of Rictor-iKOBPAs.
mTORC2 regulates histone acetylation during differentiation.
Overexpressing recombinant PPARγ2 in Rictor-iKO brown pre-
adipocytes rescues differentiation; however, supplementing rosi-
glitizone (a synthetic PPARγ ligand) cannot11, suggesting that the
mTORC2/AKT1/ACLY pathway likely regulates an early tran-
scriptional initiation event rather than a defect in endogenous
ligand synthesis and/or ampliﬁcation. Given that ACLY also
generates acetyl-CoA necessary for histone acetylation and Glut4
expression during white adipocyte differentiation30,31, we asked
whether mTORC2 might facilitate epigenetic programming dur-
ing brown adipocyte differentiation. Notably, total H3 acetylation
decreases in undifferentiated Rictor-iKOPBAs [Supplementary
Fig. 5A]. At differentiating day 2, just before Pparγ2 is initially
induced, analysis of speciﬁc acetylation marks also reveals a
marked decrease in H3K27Ac (a key marker of active enhancers
during adipogenesis32) in Rictor-iKOPBA, Akt1-iKOPBA, and Acly-
iKOPBA cell lines [Supplementary Fig. 5B–D]. Furthermore,
H3K27 acetylation in the promoter of Pparγ2 and CD36 (a Pparγ
target gene) greatly decreases in Rictor-iKOPBAs [Supplementary
Fig. 5E]. Finally, expressing recombinant Myc-ACLY-S455D in
Rictor-iKOPBAs, but not EV, Myc-ACLY-WT, or Myc-ACLY-
S455A, rescues H3K27Ac [Supplementary Fig. 5F]. Thus stimu-
lating ACLY-dependent histone acetylation during brown adi-
pogenesis is an additional mTORC2 function in brown
adipocytes.
mTORC2 regulates acetyl-CoA synthesis from acetate. While
glucose fuels acetyl-CoA synthesis through ACLY, acetyl-CoA
can also be generated from acetate through ACSS233. Therefore,
we asked whether the ability of Rictor-iKOPBAs to differentiate
might also be rescued by supplementing high levels of exogenous
acetate into the culture medium. We compared this by adding
excess exogenous citrate or pyruvate, which are acetyl-CoA pre-
cursors in the glucose pathway. Neither citrate nor pyruvate
supplementation rescues differentiation [Fig. 5a, b]. However,
supplementing acetate partially rescues lipid droplet synthesis (to
45.57% of control) and Pparγ2 expression (to 23.47% of control)
as well as protein expression without restoring acetyl-CoA level
[Fig. 5a–c, Supplementary Fig. 5G]. Interestingly, performing the
acetate supplementation experiment with Acly-iKOPBAs indicates
that acetate is nearly twice as effective at restoring lipid droplet
synthesis and Pparγ expression (to 85.4% and 44.0% of control
levels, respectively) vs Rictor-iKOPBAs [Fig. 5d, e, Supplementary
Fig. 5H]. That Rictor-iKOPBAs are less efﬁcient than Acly-iKOPBAs
at using acetate, combined with the fact that acetate supple-
mentation did not restore acetyl-CoA levels, suggested the intri-
guing possibility that mTORC2 might also regulate acetate-
derived acetyl-CoA synthesis.
To test whether mTORC2 regulates acetyl-CoA synthesis from
acetate, we performed tracer experiments by culturing Rictor-
iKOPBAs in the presence of [U-13C]-glucose (10 mM) and
physiological levels of unlabeled acetate (100 μM) or physiological
levels of [1,2-13C]-acetate (100 μM) and unlabeled glucose
(10 mM) for 1 h prior to measuring acetyl-CoA. Compared to
their isogenic controls, the percentage of labeling of acetyl-CoA
from both glucose and acetate is unchanged in Rictor-iKOPBAs
[Fig. 5f]. As total acetyl-CoA levels are halved in these cells
[Fig. 2e], this suggests that Rictor loss may reduce the ability of
cells to use either glucose or acetate to label acetyl-CoA by
roughly equivalent proportions.
In MEFs, deleting Acly upregulates acss2/ACSS2, thereby
enabling cells to engage compensatory acetate metabolism to
generate acetyl-CoA34. We reasoned that a difference in ACSS2
expression could explain why Rictor-iKOPBAs use acetate less
effectively than Acly-iKOPBAs. Like in MEFs, Acly-iKOPBAs induce
compensatory ACSS2 expression [Fig. 5g]. Glucose and acetate
tracer analysis also shows that Acly-iKOPBAs switch from using
glucose to acetate for acetyl-CoA synthesis [Fig. 5h], increasing
total cellular acetyl-CoA above normal levels (by 118.14%)
[Fig. 5i], also like in MEFs. However, this alternative pool of
acetyl-CoA is reportedly not efﬁciently used for histone
acetylation unless high levels of exogenous acetate are supple-
mented likely explaining why Acly-iKOPBAs cannot differentiate
at physiological acetate levels [Fig. 5d–e]30. Consistently, Acly-
iKOPBAs have defects in H3K9 and H3K14 acetylation in addition
to H3K27 acetylation that are all rescued with high levels of
exogenous acetate [Supplementary Fig. 5D].
In contrast, despite Rictor-iKOPBAs having nearly a 50% drop
in total acetyl-CoA levels, they fail to trigger compensatory
ACSS2 induction; in fact, ACSS2 levels are reduced in Rictor-
iKOPBA cells [Fig. 5g]. This is consistent with Rictor-deﬁcient cells
having reduced capacity to metabolize acetate. Moreover, while
Rictor-iKOPBAs and Acly-iKOPBAs overlap in having both
H3K14Ac and H3K27Ac deﬁciencies, only H3K27Ac is rescued
with high acetate supplementation in Rictor-deﬁcient cells
[Supplementary Fig. 5B, D]. Finally, we show that compensatory
ACSS2 upregulation triggered by ACLY loss is blocked when
Rictor is simultaneously knocked out [Fig. 5j] indicating the
glucose-to-acetate metabolic switch triggered upon ACLY dele-
tion also requires mTORC2. Collectively, these data reveal an
additional role for mTORC2 in promoting acetyl-CoA synthesis
from acetate at least in part by controlling ACSS2 expression.
ACLY is a key mTORC2 effector in mature brown adipocytes.
Our prior in vivo observations show that chronic mTORC2 loss
(caused by conditionally deleting Rictor in mature brown or white
adipocytes with congenitally expressed Cre drivers) attenuates
ACLY, ACC, and FASN mRNA and protein expression11–13. In
contrast, more acutely deleting Rictor in precursor brown adi-
pocytes by inducible KO reduces gluco-lipogenic ﬂux but did not
impair DNL enzyme expression [Fig. 2f, Supplementary Fig. 1B,
C]. This led us to consider whether the decrease in Acly, Acc, and
Fasn gene expression that we observe in mature brown adipocytes
may be a secondary effect of impaired ACLY function that occurs
with prolonged Rictor loss.
To investigate the temporal effect of acute vs prolonged Rictor
loss on gluco-lipogenic gene expression, we performed a time-
course analysis of ACLY phosphorylation and gene expression
following tamoxifen-induced Rictor deletion in mature brown
adipocytes (hereafter Rictor-iKOMBAs). Brieﬂy, UBC-Cre;RictorL/L
brown adipocyte precursors were treated with 4-hydroxy-
tamoxifen (4-OHT) at day 8 of differentiation, after Pparγ2
induction, to generate Rictor-iKOMBAs [Supplementary Fig. 6A,
B]. Shortly after 4-OHT treatment (corresponding to differentia-
tion day 12), mature brown adipocytes are depleted of Rictor and
have attenuated pAKTS473 and pACLYS455 [Fig. 6a]. This
coincides with a 19% reduction in acetyl-CoA levels [Fig. 6b]
and reduced H3K27Ac [Supplementary Fig. 5I]. At this time
point, ACLY, ACC, and FASN protein levels are largely
unaffected [Fig. 6a], while Acly, Acc, and Fasn mRNA show a
28.0%, 28.8% and 48.3% decrease, respectively [Fig. 6c]. We also
observe a 45.3% decrease in Chrebpβ mRNA expression, while
Chrebpα and Glut4 expression are normal [Fig. 6c]. In contrast,
more prolonged Rictor loss (differentiation day 14) results in a
62.2% decrease in Glut4 mRNA expression and depletion of
ACLY, ACC, and FASN protein [Fig. 6a, c]. In addition, ACSS2
levels decrease at day 14 consistent with mTORC2 also regulating
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Fig. 5 mTORC2 also regulates acetyl-CoA synthesis from acetate. a, b Isogenic control and Rictor-iKO brown preadipocytes were supplemented with the
indicated metabolites during differentiation and Oil Red O (ORO) staining of lipids (a) and pparγ2 mRNA expression (n= 6 per group) (b) were quantiﬁed
as indicators of differentiation efﬁciency. Percentage of ORO is relative to control in DMEM. Scale bar represents 50 μm. c Direct acetyl-CoA levels in
control and Rictor-iKOPBA cells (n= 6 per group) supplemented with unlabeled acetate (0.1 mM) or increasing [1,2-13C] acetate concentration. d, e Acly-
iKOPBA cells were differentiated with or without acetate supplementation followed by Oil Red O (ORO) staining (d) and pparγ2 mRNA expression (n= 6
per group) (e) analysis. Scale bar represents 50 μm. f M2 isotopic tracer labeling of total acetyl-CoA levels in Rictor-iKOPBA cells (n= 5 per group) that
were serum deprived for 12 h and then incubated for 1 h with fresh glucose-free DMEM supplemented with 5 mM of labeled [U-13C] glucose and 100 μM of
unlabeled acetate or unlabeled glucose and 100 μM of [1,2-13C] acetate, at 37 °C for 1 h. g Western blot showing total ACSS2 protein expression in Rictor-
iKOPBA and Acly-iKOPBA cells. hM2 isotopic tracer labeling of total acetyl-CoA levels in Acly-iKOPBA cells (n= 5) as described in f. i Direct acetyl-CoA levels
in control and Acly-iKOPBA cells (n= 5 per group). j Control and Rictor-iKO cells were stably transfected with control (scrambled-shRNA) or an shRNA
targeting ACLY. Knockdown efﬁciency and effects on ACSS2 expression were conﬁrmed by western blot. Bar graphs represent mean ± SEM. ***p < 0.001,
****p < 0.0001, a represents ***p < 0.001 vs control (EV), and b represents ***p < 0.001 vs Rictor-iKOPBA (EV) cells. Statistical signiﬁcance was calculated
by using two-way ANOVA with Sidak’s test multiple comparisons (b, c, e, f, h) or two-tailed unpaired Student’s t test (i).
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its expression in vitro in mature brown adipocytes [Fig. 6a].
These data are consistent with Rictor loss acutely impairing ACLY
activity, histone acetylation, and lipogenic gene expression, which
precedes downregulation of DNL proteins and glucose transpor-
ter expression.
Next, we asked whether expressing the recombinant Myc-
ACLY-S455D in Rictor-iKOMBAs could rescue gluco-lipogenic
gene expression. Indeed, overexpressing ACLY-S455D rescues
Acly, Acc, Fasn, Chrebpβ, and Glut4 expression and to higher than
control levels [Fig. 6d]. Interestingly, overexpressing WT-ACLY
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Fig. 6 mTORC2 drives lipogenic and Glut4 gene expression through ACLY in mature brown adipocytes. a Time-course western blots showing the
indicated phospho-speciﬁc and total proteins in Rictor-iKOMBA or Acly-iKOMBA cells following acute and prolonged protein loss. b Direct acetyl-CoA
measurements in Rictor-iKOMBA cells following acute Rictor loss (day 12) (n= 8 per group). c qRT-PCR analysis of the indicated genes following acute
(day 12) and prolonged (day 14) Rictor loss (n= 6 per group). Rictor deletion was induced at day 8 during differentiation. d qRT-PCR analysis of the
indicated genes Rictor-iKOMBA (n= 6 per group) stably expressing empty (EV), Myc-ACLY-WT, Myc-ACLY-S455A, or Myc-ACLY-455D constructs.
Bar graphs represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, a represents ***p < 0.001 vs control (EV), and b represents ***p < 0.001 vs
Rictor-iKOMBA (EV) cells. Statistical signiﬁcance was calculated by using two-tailed unpaired Student’s t test (b) or two-way ANOVA with Sidak’s test
multiple comparisons (c, d).
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also moderately rescues gene expression [Fig. 6d], while in
contrast, vector alone has little effect and ACLY-S455A has a mild
negative effect [Fig. 6d]. These data are consistent with ACLY
being a critical mediator between mTORC2, ChREBP, and gluco-
lipogenic gene expression in mature brown adipocytes.
mTORC2 and ACLY loss affect the DNL pathway in vivo.
Finally, we explored the in vivo physiological relevance of these
ﬁndings by comparing the effects of deleting Rictorl/l or Aclyl/l
alleles in BAT with Ucp1-Cre. As we recently reported13, the BAT
of Ucp1-Cre;Rictorl/l mice have dramatically attenuated Chrebpβ,
Acly, Acaca, and Fasn mRNA [Fig. 7a] and protein expression
[Fig. 7b] and small lipid droplets [Fig. 7c]. Rictor-deﬁcient BAT
also has reduced H3K27 acetylation [Supplementary Fig. 5J].
However, despite the low Acly expression, which is comparable to
deleting Acly itself, Acss2/ACSS2 levels remain largely unchanged
[Fig. 7a, b]. This is consistent with mTORC2 being necessary to
invoke the ACSS2-driven glucose-to-acetate metabolic switch. In
contrast Ucp1-Cre;Aclyl/l mice expresses higher levels of Acaca/
ACC and Fasn/FASN mRNA and protein [Fig. 7a, b] and have
larger lipid droplets [Fig. 7c]. Increased BAT lipid droplet size is
also evident in the BAT of Adiponectin-Cre;Aclyl/l mice [Sup-
plementary Fig. 7]. This phenotypic divergence correlates with
Acss2/ACSS2 expression, which is induced in Acly but not in
Rictor-deﬁcient BAT [Fig. 7a, b]. Interestingly, Chrebpβ expres-
sion decreases in the BAT of both models [Fig. 7a] indicating that
Chrebpβ may not be driving Acss2 expression in Acly-deﬁcient
BAT. This is also consistent with ChREBP functioning down-
stream of both mTORC2 and ACLY12,35.
Thus, while the effects of deleting Rictor or Acly during brown
adipocyte differentiation are largely overlapping, their loss in
mature brown adipocytes has opposite effects on ACSS2
expression, downstream DNL pathway expression, and lipid
droplet content. This is despite the fact that deleting Rictor or
Acly decreases Acly/ACLY expression to nearly the same extent.
These data are consistent with mTORC2 additionally regulating
ACSS2 in a physiologically relevant context and supports an
overarching model in which brown adipocyte mTORC2 regulates
glucose- and acetate-derived acetyl-CoA synthesis [Fig. 7d].
Discussion
Prior studies implicate adipocyte mTORC2 in controlling insulin-
stimulated glucose uptake and DNL (gluco-lipogenesis). How-
ever, the mechanism has been enigmatic because most AKT
substrates examined appear to be phosphorylated normally when
Rictor is deleted11–13. Solving this mystery is important because a
similar state of adipose tissue “selective insulin resistance” in
which insulin-stimulated glucose uptake, but not AKT activity
per se, is defective, occurs in several models of adipocyte insulin
resistance36,37. Moreover, DNL in human BAT and WAT posi-
tively correlates with thermogenesis and insulin sensitivity,
respectively15,38–40. In this study, we uncover a previously
unappreciated selectivity in mTORC2-dependent AKT signaling
toward ACLY that provides a plausible mechanistic underpinning
for why mTORC2 loss impairs brown adipocyte glucose-
dependent lipogenesis and differentiation.
One limitation of this study is that it does not address why
ACLYS455 is different from other AKT substrates. Although our
inducible KO system results in rapid loss of Rictor and AKT HM
phosphorylation, it remains possible that a compensatory
mechanism stabilizes T308 phosphorylation maintaining AKT
activity toward most substrates. A selective mTORC2 inhibitor
(i.e., which does not inhibit mTORC1) would be valuable in
determining the acute effects of mTORC2; however, such a
molecule is not yet available. Nevertheless, why would ACLY
phosphorylation differ from other AKT substrates in its
mTORC2 dependency? One possibility is that intrinsic differ-
ences in the ACLY S455 motif may demand higher AKT activity,
or a different biochemical conformation dependent on HM
phosphorylation, to be efﬁciently phosphorylated41,42. Aligning
mTORC2 dependent and independent phosphosites identiﬁed in
this study to the AKT consensus motif indicates that more
dependent sites are less conserved [Supplementary Fig. 2D].
Alternatively, the mTORC2 dependency of ACLY phosphoryla-
tion could relate to its localization and/or temporal dynamics of
phosphorylation. For example, ACLY phosphorylation may occur
distal to the plasma membrane and/or membrane PIP3 and
therefore may require HM phosphorylation to recruit PDK1,
which is how other AGC family kinases lacking PH domains are
regulated4. Indeed, evidence suggests that AKT is regulated by
both PH-domain-dependent and -independent mechanisms in
cancer cells43. Proteomics and western blotting data also indicate
that mTORC2 loss decreases ACLY phosphorylation during
serum deprivation suggesting that mTORC2 might regulate
acetyl-CoA synthesis in multiple nutritional states. Another
possibility is that mTORC2 may suppress an ACLY phosphatase.
Two studies comparing temporal dynamics of the insulin-
stimulated phosphoproteome and metabolome in 3T3-L1 adi-
pocytes show that total citrate levels acutely decrease, and acetyl-
CoA levels increase, roughly when ACLY S455 phosphorylation is
stimulated and that this occurs prior to maximum glucose
transport44,45. This suggests that mTORC2-dependent ACLY
stimulation may be an early insulin action that mobilizes meta-
bolites downstream of glucose transport, glycolysis, and the TCA
cycle to both relieve citrate’s allosteric inhibitory effect on PFK1
and prime gluco-lipogenesis. Data from this study further suggest
that mTORC2-dependent ACLY phosphorylation additionally
creates an overﬂow of acetyl-CoA that is siphoned toward histone
acetylation, thereby providing an insulin-coupled secondary epi-
genetic signal that is a direct readout of systemic nutrient (glu-
cose) availability. We suggest a model that, in brown adipocyte
precursors, this pathway provides a license for differentiation,
while in mature brown adipocytes, it potentiates glucose uptake,
glycolysis, and lipid synthesis by upregulating and/or maintaining
ChREBP activity and the gluco-lipogenic transcriptional program
[Fig. 7d]. Thus mTORC2-simulated acetyl-CoA synthesis may
provide a key missing link between systemic glucose availability
and setting the genetic program that determines the glucose- and
lipid-handling capacity of brown adipocytes.
mTORC2 also promotes Chrebpβ expression, which drives
gluco-lipogenic gene expression including that of Acly12,13.
Interestingly, Chrebpβ expression is also ACLY dependent in
white adipocytes31 consistent with ChREBPα/β functioning
downstream of mTORC2/ACLY in a positive feedback loop. Thus
ChREBP could also be the key target of mTORC2/ACLY in
gluco-lipogenic gene regulation. In fact, hepatocyte ChREBP
transcriptional activity is reportedly regulated by acetylation and
O-GlcNacylation, which both require acetyl-CoA precursors46,47.
The most likely scenario is that histone acetylation and ChREBP
activity are interconnected, and further resolving how ChREBP is
regulated by mTORC2 and ACLY will be important. The
mTORC2/ACLY pathway might additionally regulate other
posttranslational modiﬁcations or allosteric regulatory roles
linked to DNL metabolites, such as palmitoylation, which is
implicated in Glut4 trafﬁcking48,49. The potential role of DNL as
a source of signaling metabolites in adipocytes has been under-
appreciated, but it is tempting to speculate that defects in their
second messenger functions could be key steps in the early onset
of insulin resistance.
That mTORC2 additionally regulates acetyl-CoA synthesis
from acetate indicates a broader role of mTORC2 in controlling
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Fig. 7 In vivo, mTORC2 and ACLY both promote ChREBPβ expression, but their loss has opposite effects on ACC and FASN expression that correlates
with differential ACSS2 regulation. a qRT-PCR analysis of the indicated genes in brown fat tissue isolated from control (Rictorl/l and Aclyl/l) or UCP1-Cre-
Rictorl/l and UCP1-Cre-Aclyl/l mice (n= 6 per group). Bar graphs represent mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical signiﬁcance was
calculated by using two-way ANOVA with Sidak’s test multiple comparisons (a). b Corresponding western blots for a. Black arrows indicate the ACC1 and
ACC2 isoforms. c Hematoxylin and eosin stains showing brown fat morphology for the indicated genotypes. Scale bar represents 200 μm. d Our results
support the following model of mTORC2 action in brown adipocytes: (1) mTORC2-dependent AKT phosphorylation is distinctly important for ACLY
phosphorylation, while for many other AKT substrates, mTORC2 may normally facilitate their phosphorylation, but it is dispensable (indicated by “P” within
an unshaded broken circle). This is indicated by the fact that phosphorylation of many AKT substrates is unimpaired by Rictor deletion while ACLY
phosphorylation is reduced. (2) mTORC2/AKT-dependent ACLY phosphorylation promotes acetyl-CoA synthesis and primes de novo lipogenesis
downstream of glucose uptake and glycolysis. (3) The increased ﬂux to acetyl-CoA additionally stimulates histone acetylation. In brown adipocyte
precursors, this coincides with pparγ induction to drive differentiation; in mature brown adipocytes, this coincides with ChREBPβ activity to increase
expression of gluco-lipogenic genes. (4) Gluco-lipogenic gene expression then provides a positive feedback effect on glucose transport and de novo
lipogenesis. (5) mTORC2 may also stimulate acetate metabolism to acetyl-CoA by regulating the expression and/or activity of ACSS2. Notably, from these
data we cannot distinguish between cytoplasmic and nuclear pools of acetyl-CoA.
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nuclear–cytoplasmic acetyl-CoA synthesis. The role of acetate as a
metabolic substrate in adipocytes is not well understood. How-
ever, the differential effects on ACSS2 expression caused by Rictor
loss vs Acly loss could explain why Adiponectin-Cre;Rictorl/l mice
have a more severe metabolic phenotype compared to Adipo-
nectin-Cre;Aclyl/l mice12,34. In conclusion, the identiﬁcation of
ACLY and ACSS2 as key targets of mTORC2 action in brown
adipocytes ﬁlls an important gap in our understanding of this
more mysterious mTOR complex. These ﬁndings may be relevant
to understanding mTORC2 action in other tissues and in the
pathogenesis of type-2 diabetes.
Methods
Mice. C57BL/6J mice (JAX stock 000664) were obtained from Jackson Laboratory.
Ucp1-Cre (JAX stock 024670) and Adiponectin-Cre (JAX stock 010803) were kindly
provided by Dr. Evan Rosen. Akt1l/l, Akt2l/l, and Akt3-KO mice were kindly
provided by Dr. Birnbaum MJ. Ubc-CreERT2; Rictorl/l mice and Aclyl/l mice were
generated by crossing UBC-CreERT2 with Rictorl/l or Aclyl/l mice11,34. UBC-
CreERT2; Akt1l/l, Akt2l/l, Akt3-KO were generated by crossing UBC-CreERT2; Akt1l/l
with UBC-CreERT2; Akt2l/l until UBC-CreERT2; Akt1l/l, Akt2l/l was obtained and
then once more to Akt3-KO mice until we obtained the ﬁnal Ubc-CreERT2; Akt1l/l,
Akt2l/l, Akt3-KO genotype. Mice were housed in the UMMS Animal Medicine
facilities in a room set at 22 °C in 45% humidity under daily 12 light/dark cycles.
For all in vivo studies, we used 8-week-old Ucp1-Cre-Rictorl/l and Ucp1-Cre-Aclyl/l
mice. We have complied with all relevant ethical regulations for animal testing and
research, and all animal studies have been approved by the Umass Medical School
Committee on Animal Care (IACUC).
Cultured cells. Brown preadipocytes were isolated from Ubc-CreERT2; Rictorl/l,
Ubc-CreERT2; Aclyl/l, or Ubc-CreERT2; Akt1l/l, Akt2l/l, Akt3−/− P1 neonates and
immortalized with pBabe-SV40 Large T according to a standard protocol50. Cells
stably expressing recombinant proteins were obtained either by using lentiviral
(TRCN 0000055214-17) and Rictor (addgene: P1853/1854) shRNA experiments or
retroviral systems (e.g., Glut-1, HK, Akt, and Acly experiments). For brown adi-
pocyte differentiation, cells were seeded and allowed to proliferate to conﬂuence in
the presence of differentiation medium that includes 20 mM of insulin and 1 nM of
T3. At day 4, cells were treated with induction medium containing 20 mM of
insulin, 1 nM of T3, 0.125 mM of indomethacin, 2 μM/mL dexamethasone, and 0.5
mM 3-isobutyl-1-methylxantine (IBMX) for 2 days. Then the induction medium
was replaced with differentiation medium that was changed every 2 days until day
14. Deletion of Rictor, Acly, Akt1, and/or Akt2 was achieved by treating the cells
with two doses of 4-OHT (1 μM) prior to the start of differentiation (to obtain
Rictor-iKOPBA cells) or one dose at day 8 of differentiation (to obtain Rictor-
iKOMBA cells) depending on the experiment. Control cells received an equivalent
dose of ethanol (vehicle). To analyze insulin or fetal bovine serum (FBS) signaling,
cells were serum deprived for 12 h and then stimulated with insulin (150 nm) or
10% FBS for 15 min. To analyze AKT dependency, cells were treated with or
without AKT inhibitor MK2206 (10 μM). For metabolite rescue experiments,
pyruvate (2.5 mM), citrate (2.5 mM), or sodium acetate (5 mM) was added in every
media change to the corresponding differentiation or induction media. For Myc-
ACLY-WT, Myc-ACLY-S455A, and Myc-ACLY-S455D overexpression experi-
ments in Rictor-iKOMBA, cells were infected at day 10 of differentiation and col-
lected at day 14. HEK293E cells were grown in 10% FBS in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) and infected with pLentiCRISPRv2 (addgene:52961)
with a guide targeting the ﬁrst exon of Rictor (CCCGTCAATATGGCGGCGTC
GG) and were selected in puromycin for 4 days. Rictor KO was validated by
western blot. Rictor was re-expressed in these cells and validated by western blot.
Antibodies and reagents. GLUT-1 (ab652) and H3K27Ac (ab4729) were pur-
chased from Abcam. HK (A0994) and horseradish peroxidase (HRP)-goat anti-
Rabbit were purchased from ABclonal. HRP-conjugate anti-mouse (w402b) was
purchased from Promega. H2BK (07-373), H4K (06-866), and H3K (06-599) were
purchased from Millipore. Flag (F7425) was purchased from Sigma-Aldrich. All
other antibodies including Rictor (2140), PRAS40 (2691), AKT (9272), GSK3b
(9315), ACC (3676), ACLY (4332), FASN (3180), PPARg (2443), ACSS2 (3658), S6
(2217), S473-AKT (4058), T308-AKT (4056), S455-ACLY (4331), T246-pPRAS40
(2997), HA-tag (2367), S9-GSK3b (9315), S235/236-S6 (4858), H3 (9715), H3K9Ac
(9649), H3K14Ac (7627), and a-Tubulin (2125) were purchased from Cell Sig-
naling Technologies. 4-OHT was obtained from Toronto Research Chemicals. D-
[U-14C]-glucose (NEC042V250UC) was purchased from Perkin Elmer. MK2206
(S1078) was purchased from Selleck Chemicals. T3 (T2877), dexamethasone
(D1756), IBMX (I5879), and insulin (I2643) were from Sigma-Aldrich. [U-13C]
glucose (CLM-1396-1) and [1,2-13C] acetate (CLM-440-PK) were purchased from
Cambridge Isotope Laboratories, Inc.
Western blot analysis. Cells were homogenized in a Triton-X lysis buffer
containing 150 mM NaCl, 50 mM Tris pH 7.5, 0.5% deoxycholate, 1% Triton X-
100, and 0.1% sodium dodecyl sulfate (SDS); a protease inhibitor cocktail
(Biotool Cat. Number); and a phosphatase inhibitor cocktail (Sigma Cat.
Number P5726). For in vivo analysis, each tissue was collected and frozen down
immediately in liquid nitrogen and then stored at −80 °C for subsequent lysis.
Tissues were homogenized using a TissueLyser (Qiagen) in RIPA lysis buffer
containing 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, and 50 mM
Tris, pH 7.5 including a protease (Biotool Cat. Number B14011) and phos-
phatase inhibitor cocktail (Sigma Cat. Number P5726). An equal amount of total
protein was loaded into either 10% acrylamide/bis-acrylamide gels for general
analysis or 16% acrylamide/bis-acrylamide gels for histone analysis and trans-
ferred to polyvinylidene ﬂuoride membranes. Ponceau stain was performed to
check for equal transfer and loading. Membranes were incubated in either 5%
milk/phosphate-buffered saline with Tween detergent (PBST) or 5% bovine
serum albumin (BSA)/PBST for 1 h and with primary antibodies (1:1000 dilu-
tion) in 5% milk/PBST or 5% BSA/PBST overnight, washed 3 times with PBST,
and then incubated with the correspondent secondary antibody for 2 h. Tubulin
was used as an additional protein level control where indicated. HRP-conjugated
secondary antibodies (1:10,000 dilution) were given for 1 h. Western blots
were developed by enhanced chemiluminescence (PerkinElmer) and detected by
X-ray ﬁlms.
Chromatin extraction. Chromatin extraction was performed prior to the western
blot analysis51. Brieﬂy, cells were collected at day 2 of the differentiation assay,
before Pparγ2 induction, resuspended in lysis buffer (10 mM Hepes pH 7.4, 10 mM
KCl, 0.05% NP-40, and a protease (Biotool Cat. Number B14011) and phosphatase
inhibitor cocktail (Sigma Cat. Number P5726)) and incubated on ice for 20 min.
Then the samples were centrifuged at 16,000 × g for 10 min after which the nuclear
pellet was resuspended in HCl 0.2 N and incubated on ice for an additional 20 min.
Samples were centrifuged at 16,000 × g for 10 min, and the supernatant containing
the chromatin was neutralized in Tris-HCl pH 8 1M.
Glucose uptake. Cells were preincubated for 3 h in a medium without glucose
(KRH medium (Gibco plus 0.5% BSA+ 2 mM pyruvate). Deoxy-D-glucose 2-[1,2-
3H(N)] was then added, and incubation was continued for an additional 10 min.
The medium was then removed and cells were washed three times with KRH
medium to terminate the assay. Cells were then lysed in 1% triton, mixed with
scintillation buffer, and the uptake of 3H glucose was quantiﬁed in counts per
minute (cpm) using a scintillation counter. The cpm values were normalized to the
protein concentration of each sample.
Phosphoproteomics. Control and Rictor-iKO cells were serum deprived for 12 h
(unstimulated samples) and then some were treated with 150 nM insulin for 15
min (stimulated). All cells were washed 3 times with cold PBS, snap-frozen in
liquid nitrogen, and thawed in a lysis buffer (8 M urea, 50 mM Tris pH 8.2, 75 mM
NaCl, 50 mM β-glycerophosphate, 1 mM sodium orthovanadate, 10 mM sodium
pyrophosphate, 50 mM sodium ﬂuoride, and 1× EDTA-free protease inhibitor
cocktail (Roche)). Each well of a 6-well plate was scraped in 125 μL of ice-cold lysis
buffer, and 2 wells were pooled for each replicate. Lysates were probe-sonicated two
times, and clariﬁed by centrifugation at 16,000 × g. Protein content was measured
by a BCA assay (Pierce). Samples were reduced for 45 min at 55 °C using 5 mM
dithiothreitol, alkylated with 15 mM iodoacetamide for 30 min in the dark at room
temperature, and quenched with an additional 5 mM of dithiothreitol at room
temperature for 15 min. Urea was diluted to 1.5 M using 50 mM pH 8.2 Tris, and
protein was digested for 16 h using 5 μg/mL trypsin at 37 °C. Digested peptides
were de-salted using 50 mg Sep-Pak cartridges (Waters) and dried by vacuum
centrifugation. Phosphopeptides were enriched using PureCube Fe-NTA magnetic
beads (Cube Biotech) in a KingFisher magnetic bead processor (Thermo). Dried
phosphopeptide samples were prepared for analysis by liquid chromatography
coupled to tandem mass spectrometry (LC-MS/MS) by dissolution in 4% formic
acid and 3% acetonitrile.
To screen for mTORC2-dependent phosphorylation, we designed a targeted,
parallel reaction monitoring (PRM) mass spectrometry method that was informed
by manual literature curation and prior preliminary experiments. To design the list,
we curated a preliminary list of 228 phosphopeptides representing previously
characterized AKT substrates, regulatory phosphorylation sites on AGC kinases,
phosphorylation sites on proteins with known regulatory function in insulin
signaling and/or brown fat, and phosphorylation sites with potential mTORC2
dependence according to preliminary, unpublished data. According to a previously
reported method52, we referenced an in-house database of mouse
phosphoproteome data gathered from several different tissues using data-
dependent acquisition (DDA) to determine the best phosphopeptide(s) with which
to represent each phosphorylation site. Speciﬁcally, for each phosphorylation site,
we determined which charge state and peptide cleavage form was the most
frequently observed in the DDA data. Importantly, this database also enabled
accurate prediction of the chromatographic retention time. In some cases,
phosphorylation sites were represented by multiple peptides in the preliminary
target list because it was not obvious which peptide form to choose. To reﬁne the
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preliminary target list, three separate PRM assays were used to measure these
phosphopeptides in insulin-stimulated WT cells with wide (+/−2.5 min) windows
for retention time prediction. Peptides that were not detected or contained
complete overlap of phosphorylation sites with another detected peptide were
removed from the list, and all retention time predictions were re-calibrated. This
ﬁnal target list was then used for PRM analysis of all the samples with narrow
(+/−1.5 min) windows for retention time prediction.
Targeted phosphoproteomic analysis of preadipocyte phosphorylation sites
was performed using LC-MS/MS. To normalize for injection amount during LC-
MS/MS analysis, we measured all samples using DDA and identiﬁed 12
phosphopeptides that correlated strongly with the total MS signal and spanned
most of the retention time space. DDA analysis was performed on a Thermo
QExactive mass spectrometer connected to a Thermo Easy-nLC II.
Chromatographic separation was performed on a 30-cm length column with a
100-μm internal diameter, packed with Reprosil 1.9 μm C18 beads (Dr. Maisch
GmbH). The LC method consisted of a 49-min linear gradient from 9% to 25%
acetonitrile in 0.15% formic acid. Data were acquired throughout a 70-min total
time. Full MS scans were acquired from 300 to 1500m/z at 70,000 resolution
with an AGC target of 3 × 106 and a maximum injection time of 240 ms. The top
20 most abundant precursors per MS scan were isolated with a 2-m/z window,
an AGC target of 2 × 105, a maximum injection time of 120 ms, and 40 s
dynamic exclusion. Isolated precursors were fragmented by high-energy
collision-induced dissociation at a normalized collision energy of 27%, and MS/
MS were acquired at 17,500 resolution. Targeted LC-MS/MS using PRM was
performed on the same instrument set-up as for DDA. The instrument methods
were mostly the same as for the DDA analysis, except that MS/MS spectra
were acquired according to the predeﬁned schedule of precursors representing
the phosphopeptide target list, as described above. Every 20 scans, a full MS scan
was acquired as described above for DDA. All MS and MS/MS spectra for
DDA and PRM experiments were collected in centroid mode. PRM data were
analyzed using Skyline53, and all chromatographic peaks and phosphorylation
site localizations were manually inspected. For additional veriﬁcation of
phosphorylation site localization, PRM data were searched using Comet
(v2015.02.5)54 and ﬁltered at 1% FDR using Percolator55. Each MS/MS
spectrum was scored for localization using Ascore56. Ascore values representing
conﬁdence of site localization were plotted vs retention time and manually
compared to the fragment chromatographic elution peaks in Skyline.
Phosphorylation sites were stratiﬁed into three categories of mTORC2 sensitivity
by calculating ANOVA statistics to determine the signiﬁcant effects of Rictor
loss and correcting to q-values using the Benjamini–Hochberg method. Class I
sites had q ≤ 0.05 and at least a 2-fold difference between control and Rictor-
iKOPBA. Class III sites had q ≤ 0.05 and at least a 1.33-fold difference between
control and Rictor-iKOPBA. All the phosphoproteomic data generated during this
study are available and were deposited in Massive.Ucsd.edu [https://massive.
ucsd.edu/ProteoSAFe/dataset.jsp?task=2335fcac3c184be69e7efe068387f771].
Metabolite analysis. Cells were incubated in serum-free media for 12 h and then
incubated for 3 h with fresh DMEM medium. Samples were prepared by per-
forming an 80% methanol extraction and stored at −80 °C until shipping. Polar
metabolite proﬁling methods were developed at the Whitehead Institute for Bio-
medical Research Metabolomics core facility, where the measurements were per-
formed. Reference standards of each metabolite were used to determine
chromatographic retention times and MS multiple reaction monitoring transitions,
declustering potentials, and collision energies. All metabolites were normalized to
the protein concentration of each sample.
Chromatin immunoprecipitation analysis. Cells were cross-linked with 1%
paraformaldehyde for 15 min at room temperature. The reaction was quenched
for 5 min at room temperature by adding 0.125 M glycine. After three washes
with 1× PBS, cells were lysed with lysis buffer (1% SDS, 20 mM EDTA pH 8,
50 mM Tris-HCl, pH 8) supplemented with protease and deacetylase (TSA)
inhibitors. Lysates were sonicated on ice using a Diagenode BioruptorTM
UCD200 sonicator (for 15 min total at high setting in intervals of 45 s on–20 s off
and kept on ice during the whole sonication process). Size of fragments obtained
(between 200 and 1200 bp) was conﬁrmed by electrophoresis. Soluble chromatin
was collected after centrifugation at 16,000 × g at 4 °C for 10 min. Soluble
chromatin (1%) was kept as input control. Soluble chromatin was precleared
with 2.5 μg/mL of protein-A-Sepharose at 50% at 4 °C in rotation for 1 h and
beads were spin down at 5900 × g for 3 min at 4 °C. After centrifugation,
supernatants were collected and speciﬁc antibodies (for total H3: Cell Signaling
#9715; and for K27H3Ac: Abcam ab4729) were added. Mixtures were incubated
overnight at 4 °C for 8 h in rotation and then incubated for 2 h at 4 °C in rotation
with protein-A-Sepharose at 50% (Roche). Beads were collected and washed
sequentially at 4 °C for 10 min with wash buffer A (140 mM NaCl, 0.1% SDS,
0.1% deoxycholate, 1% Triton X-100, 1 mM EDTA, and 50 mM Hepes (pH 7.9)),
wash buffer B (500 mM NaCl, 0.1% SDS, 1% Triton X-100, 0.1% deoxycholate,
1 mM EDTA, and 50 mM Hepes (pH 7.9.1)), LiCl buffer (20 mM Tris-HCl
(pH 8), 1 mM EDTA, 250 mM LiCl, 0.5% deoxycholate, and 0.5% NP-40),
and TE buffer (10 mM Tris-HCL (pH*), 1 mM EDTA). Immunoprecipitates
were eluted two times with elution buffer elution buffer (50 mM Tris-HCl
(pH 8), 1 mM EDTA, and 1% SDS). Reversion of cross-linking was performed
overnight by heating samples and input controls at 65 °C. Samples were then
treated with 0.2 mg/mL RNAse A (Qiagen) and incubated for 30 min at 37 °C
followed by addition of 1 μL of (20 mg/mL) Proteinase K (Promega), and sam-
ples were incubated at 45 °C for 1 h. DNA was then puriﬁed using the QIAquick
Spin Kit (Qiagen). Real-time reverse transcriptase PCR was performed with
primers listed in Supplementary Table 1.
Acetyl-CoA measurements and isotopic tracer analysis. Cells were fasted for
12 h and then incubated in DMEM without glucose plus 5 mM of normal or 3C6-
glucose and 100 μM normal or 13C2 acetate at 37 °C for 1 h. Samples were har-
vested in cold PBS, centrifuged 1000 × g, 5 min, and the pellet was quenched in 10%
(w/v) ice cold trichloroacetic acid in water, and then frozen at −80 °C until
extraction and analysis on a QExactive Plus (Thermo) mass spectrometer coupled
to an Ultimate 3000 high-performance LC. For quantitation, the abundance of
acyl-CoA species was determined by interpolation to a linear standard curve. For
isotopic tracer analysis, isotopic enrichment was calculated to compensate for the
non-linearity of isotopic enrichment using the FluxFix calculator57.
De novo lipogenesis assay. Cells were incubated for 3 days with DMEM in which
0.01% of the total glucose concentration of the medium was comprised of D-[U-
14C]-glucose. Chloroform extraction was performed, and labeled lipids were
measured using a scintillation counter. Each sample was normalized to total pro-
tein concentration58.
Lipid staining. Cells were ﬁxed with 4% paraformaldehyde, washed with distilled
water, and treated with 100% propylene glycol twice for 5 min followed by a 15-
min incubation with Oil Red O solution. Then cells were washed with 85% pro-
pylene glycol for 3 min and rinsed twice in distilled water. Oil Red O stain was
quantiﬁed with the ImageJ software (http://imagej.net/Welcome) and in each case
shows the average quantiﬁcation of four images representing each quadrant of
the well.
Gene expression analysis. Cells or tissues were lysed with Qiazol (Invitrogen) and
total RNA was isolated with the RNeasy Kit (Invitrogen). Equal amounts of RNA
(2 μg) were retro-transcribed to cDNA using a high-capacity cDNA Reverse
Transcription Kit (#4368813, Applied Biosystems). Quantitative real-time PCR was
performed in 10 μL reactions using a StepOnePlus real-time PCR machine from
Applied Biosystems using SYBR Green PCR master mix (#4309156, Applied Bio-
systems) according to the manufacturer’s instructions. Relative mRNA expression
was determined by the ΔΔCt method and Tbp expression was used as a normal-
ization gene in all conventional PCR with reverse transcription experiments. Pri-
mer information is listed in Supplementary Table 1.
Quantiﬁcation and statistical analysis. Data are presented as mean+ SEM; *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, a represents ***p < 0.001 vs control
(EV), and b represents ***p < 0.001 vs iKO (EV) unless stated otherwise. Student’s t
test or two-way ANOVA with the Sidak’s test, as appropriate, was used to deter-
mine statistical signiﬁcance. Statistical analysis was done using GraphPad Prism.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All the phosphoproteomic data generated during this study are available in Massive.Ucsd.edu
[https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=2335fcac3c184be69e7efe068387f771]
and the analysis performed is shown in Supplementary Data 1. All other materials, data, and/
or associated protocols will also be made available upon request.
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